Nuvalent (NUVL) Stock Price, News & Analysis

Company Overview

Nuvalent, Inc. (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations. These assets are being evaluated in multicenter Phase 1/2 clinical trials across the United States and Europe, with early data demonstrating favorable safety profiles and preliminary signs of clinical activity in patients with RET-driven and KRAS-mutant solid tumors. In addition to these core programs, Nuvalent continues to leverage its structure-based approach to advance discovery efforts and expand its portfolio into other oncogenic targets.

The company conducts its operations primarily in North America, supported by strategic collaborations and investigator-led studies in international research centers. Under the leadership of President and Chief Executive Officer Bill Haney, Nuvalent has assembled a management team with extensive experience in oncology drug development, regulatory affairs and commercial planning. The organization remains committed to translating cutting-edge science into precision medicines that address unmet needs in cancer therapy.

Key Stats

• Today's Range: $123.96 to $123.96
• 50-Day Range: $123.25 to $123.96
• 52-Week Range: $71.13 to $123.99
• Volume: N/A
• Average Volume: 1.93 million shs
• Market Capitalization: $9.79 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $128.99
• Consensus Rating: Hold

Company Calendar

• Last Earnings: 5/07/2026
• Today: 9/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NUVL
• CIK: 1861560
• Web: www.nuvalent.com
• Phone: 857-357-7000
• Fax: N/A
• Employees: 40
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Nuvalent: $128.99
• High Price Target: $165.00
• Low Price Target: $122.85
• Potential Upside/Downside: +4.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.15
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$425.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -40.11%
• Return on Assets: -35.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.14
• Quick Ratio: 16.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.95 per share
• Price / Book: 7.77

Miscellaneous

• Outstanding Shares: 78,998,000
• Free Float: 75,032,000
• Market Cap: $9.79 billion
• Optionable: Optionable
• Beta: 1.14